Generate Biomedicines, Inc. (GENB) Institutional Ownership & Insider Trading
86 institutions reported holding Generate Biomedicines, Inc. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 8 insider trades on Form 4 since 2025-10-01.
Source: SEC EDGAR filings · read by EquiReason
GENBGenerate Biomedicines, Inc.Follow GENB — free
—
Price chart with a free account
- Market cap
- 1.6B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Institutions · all 13F filers
quarter to 30 Jun 2026 · filers in both quarters86 institutions held 78.0% of the shares. Across filers that reported both quarters, shares held changed +5.5%.
Largest moves, shares (millions)
Institutional flow by quarter
net shares added or trimmed, millions · filers in both quarters| Quarter | Holders | Shares held, M | Change | Increased | New | Decreased | Closed |
|---|---|---|---|---|---|---|---|
| Jun 26 | 86 | 100 | +5.5% | 24 | 41 | 10 | 13 |
| Mar 26 | 57 | 93 | — | — | — | — | — |
Generate Biomedicines, Inc. — questions
- Who owns Generate Biomedicines, Inc. stock?
- 86 institutions reported Generate Biomedicines, Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: Flagship Pioneering, LLC (48.8%), FMR LLC (4.1%), Capital World Investors (3.3%).
- Are Generate Biomedicines, Inc. insiders buying or selling?
- 8 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.
Every figure on this page comes from Generate Biomedicines, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.